Immunotherapy Research and Treatment Center

The Immunotherapy Research and Treatment Center (IRTC) is a specialized clinical research and patient care facility within The Angeles Clinic and Research Institute, a part of Cedars-Sinai. Globally recognized for its pioneering role in cancer immunotherapy, the center has been a lead site for pivotal clinical trials of landmark drugs such as pembrolizumab (Keytruda) and nivolumab (Opdivo). The IRTC provides comprehensive care including Phase I-III clinical trials, advanced diagnostics, and personalized treatment plans for patients with melanoma, lung cancer, and other solid tumors. Its research programs focus on novel therapeutic modalities such as checkpoint inhibitors, cell therapies, and cancer vaccines. The center's expertise and high-volume trial capacity make it a critical partner for major pharmaceutical and biotechnology companies in the oncology space.